تحليلات المنتج الاختيارية
بإذنك، نستخدم تحليلات محدودة تراعي الخصوصية لفهم مسارات البحث الفعالة. لا نستخدم أدوات تتبع إعلانية أو تسجيل الجلسات. يمكنك تغيير هذا الخيار في التفضيلات. اقرأ سياسة الخصوصية.
Bull: Revenue accelerates beyond the historical 4.82% CAGR toward the 6.12% next-year estimate, driven by successful pipeline commercialization.
The 97.7% dividend payout ratio eliminates capital flexibility, making margin stability absolutely paramount to the thesis.
Sanofi is a mature, dividend-paying global pharmaceutical company currently trading at a steep discount to major peers (8.4x forward P/E vs peer median 14.0x). Generating robust free cash flows ($7.2B in the latest year), it supports a strong 5.55% dividend yield. While historical revenue growth is moderate, near-term estimates suggest stable low-to-mid single-digit expansion.
Sanofi is a mature, dividend-paying global pharmaceutical company currently trading at a steep discount to major peers (8.4x forward P/E vs peer median 14.0x). Generating robust free cash flows ($7.2B in the latest year), it supports a strong 5.55% . While historical is moderate, near-term estimates suggest stable low-to-mid single-digit expansion.
Scale in immunology, vaccines, and rare diseases
Robust absolute free cash flow generation ($7.2B)
Acceleration in immunology and rare disease commercialization, expanding operating margins.
Buy.
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Top-line growth stagnates near 1% as the pipeline fails to offset competitive pressures across core segments. With the payout ratio already at 97.73%, any margin contraction creates severe risk of a dividend freeze or cut. Valuation multiple remains trapped.
Top-line growth stagnates near 1% as the pipeline fails to offset competitive pressures across core segments. With the payout ratio at 97.73%, any margin contraction creates severe risk of a dividend freeze or cut, trapping the multiple at 8.0x.
Operating margin dips below the 20.00% trailing average, compressing available free cash flow.
التطورات الخمسة التي قد تضعف أطروحتنا الاستثمارية.
Sustained profitability contraction erodes cash conversion efficiency and reduces internal funding capacity needed to support extensive late-stage clinical trials, increasing dependence on external capital.
الحالي:Operating margin was 20.5% for the period ended 2025-12-31
تنبيه إذاDeclines below 20.0% over any trailing twelve-month period
Scale in immunology, vaccines, and rare diseases
Robust absolute free cash flow generation ($7.2B)
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Apply a terminal P/E to the dated forward path, then discount that future share value back to the analysis date.
Unavailable
The highlighted base cell is anchored to composite fair-value midpoint ($51.15). It is the reference value for this grid, not a separate standalone fair-value claim.
FCFF DCF remains positive at the base case: base FCFF $9.1B after capex $4.1B, with terminal value at 56.8% of enterprise value. No FCF cliff is projected unless capex/revenue or gross margin materially resets.
Revenue accelerates beyond the historical 4.82% CAGR toward the 6.12% next-year estimate, driven by successful pipeline commercialization. Operating margins improve past 20%, and the equity partially re-rates toward the peer median.
If forward revenue growth > 4.82% and margins > 20%, market begins re-rating terminal multiple toward 12x. If margins < 20%, dividend cut fears trigger multiple compression toward 8x.
If forward revenue growth > 4.82% and margins > 20%, market begins re-rating terminal multiple toward 12x. If margins < 20%, dividend cut fears trigger multiple compression toward 8x.
If forward revenue growth > 4.82% and margins > 20%, market begins re-rating terminal multiple toward 12x. If margins < 20%, dividend cut fears trigger multiple compression toward 8x.
If forward revenue growth > 4.82% and margins > 20%, market begins re-rating terminal multiple toward 12x. If margins < 20%, dividend cut fears trigger multiple compression toward 8x.
Warning level: Declines below 20.0% over any trailing twelve-month period. Sustained profitability contraction erodes cash conversion efficiency and reduces internal funding capacity needed to support extensive late-stage clinical trials, increasing dependence on external capital.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| الإيرادات | 46,716,000,000 |
|---|---|
| تكلفة الإيرادات | 13,049,000,000 |
| إجمالي الربح | 33,667,000,000 |
| المصروفات التشغيلية | 24,070,000,000 |
| الدخل التشغيلي | 9,597,000,000 |
| البنود غير التشغيلية والضرائب | -1,784,000,000 |
| صافي الدخل | 7,813,000,000 |
| إجمالي الأصول | 126,805,000,000 |
|---|---|
| النقد | 7,657,000,000 |
| الأصول المتداولة | 30,952,000,000 |
| إجمالي الالتزامات | 55,095,000,000 |
| الالتزامات المتداولة | 28,345,000,000 |
| حقوق المساهمين | 71,376,000,000 |
البيانات المالية في نقطة زمنية المستخدمة في تحليل 2026-05-20.
| الفترة | الإيرادات | EBITDA | صافي الدخل | التدفق النقدي التشغيلي | التدفق النقدي الحر | النفقات الرأسمالية | الإهلاك والإطفاء | التعويض القائم على الأسهم | إعادة شراء الأسهم | أرباح الأسهم المدفوعة | صافي إصدار الدين | التدفق النقدي الاستثماري | التدفق النقدي التمويلي | النقد في بداية الفترة | النقد في نهاية الفترة | النقد والاستثمارات | إجمالي الديون | الهامش التشغيلي | ROIC | WACC | فارق ROIC−WACC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | 40.6 مليار | 13.5 مليار | 8.4 مليار | 10.5 مليار | 8.4 مليار | 2.1 مليار | 3.1 مليار | — | 497 مليون | 4.2 مليار | -1.2 مليار | — | — | — | — | 12.7 مليار | 21.2 مليار | 26.9% | — | — | — |
| 2023-12-31 | 41.6 مليار | 11.3 مليار | 5.4 مليار | 10.3 مليار | 7.4 مليار | 2.9 مليار | 4.4 مليار | — | 593 مليون | 4.5 مليار | -3.1 مليار | — | — | — | — | 8.7 مليار | 18.4 مليار | 20.9% | — | — | — |
| 2024-12-31 | 44.3 مليار | 11 مليار | 5.6 مليار | 9.1 مليار | 5.9 مليار | 3.2 مليار | 3.6 مليار | — | 302 مليون | 4.7 مليار | -894 مليون | — | — | — | — | 7.4 مليار | 17.9 مليار | 20.1% | — | — | — |
| 2025-12-31 | 46.7 مليار | 12.5 مليار | 7.8 مليار | 10.8 مليار | 7.2 مليار | 3.5 مليار | 5.7 مليار | — | 5 مليار | 4.8 مليار | 1.5 مليار | — | — | — | — | 7.7 مليار | 20.3 مليار | 20.5% | — | — | — |
SNY trades at 8.4x forward earnings against a peer median of 14.1x; EV/EBITDA of 5.2x against a peer median of 14.5x; 6 peers.
Normal capex phase (7.57% of revenue). Reinvestment severely restricted by the 97.7% dividend payout structure.
Acceleration in immunology and rare disease commercialization, expanding operating margins.
Patent cliffs and generic market penetration compressing legacy pricing power.
Normal capex phase (7.57% of revenue). Reinvestment severely restricted by the 97.7% dividend payout structure.
Standard weight.
Trim exposure if the operating margin falls below 20.0%, which would critically threaten the 97.7% dividend payout structure.
Buy.
Trading at a steep discount (8.4x vs 14.0x peer median) reflecting unjustified pessimism over mature pipeline assets.
Buy.
Downside case: The 97.7% dividend payout ratio eliminates capital flexibility, making margin stability absolutely paramount to the thesis.
دوّن أطروحتك الاستثمارية وحجم مركزك وأسئلة المتابعة. تبقى على هذا الجهاز، ولا يراها أحد سواك.
The 97.73% payout ratio forces a dividend cut due to unexpected top-line stagnation near 1%.
Pipeline fails to offset competitive pressures across core immunology and oncology commercial segments.
Top-line stagnation indicates commercial portfolio exhaustion and an inability to offset loss of exclusivity, impairing operational leverage and constraining enterprise reinvestment.
الحالي:Revenue growth was 5.5% for the period ended 2025-12-31
تنبيه إذاSlows to 1.0% or lower for two consecutive fiscal years
Clinical setbacks eliminate anticipated successor revenue streams required to replace maturing legacy blockbusters, exposing the business to patent cliffs and severe volume losses.
الحالي:Active clinical pipeline across core immunology and oncology segments as of 2026-05-20
تنبيه إذاFiled regulatory rejection, trial termination, or clinical suspension of a lead Phase 3 candidate within 12 months
Distributing more cash than generated forces management to divert liquidity from capital expenditures or take on debt to sustain shareholder distributions, creating imminent risk of distribution reductions.
الحالي:Payout ratio of 97.73% as of 2026-05-20
تنبيه إذاExceeds 100.0% over any trailing twelve-month period
Cash generation lagging reported earnings highlights working capital absorption or aggressive revenue accruals, undermining earnings quality and reducing discretionary cash available for balance sheet flexibility.
الحالي:Operating cash flow to net income was 1.376 as of the report's 2026-05-20 analysis date
تنبيه إذاDrops below 1.0x over any four-quarter measurement period
| Monitor the threat against the report checkpoints. |
This edition does not contain enough finite inputs to reproduce the lens calculation.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and terminal value at WACC, then adjust for signed net debt per current share.
This edition does not contain enough finite inputs to reproduce the lens calculation.
Discount the explicit dividend path and its Gordon-growth terminal value at cost of equity.
This edition does not contain enough finite inputs to reproduce the lens calculation.
Growth remains stable, anchored by vaccines and rare diseases. The 12.0x terminal multiple reflects a conservative partial re-rating from the current 8.4x, deliberately constrained below peers due to the rigid 97.7% dividend payout policy.
Warning level: Slows to 1.0% or lower for two consecutive fiscal years. Top-line stagnation indicates commercial portfolio exhaustion and an inability to offset loss of exclusivity, impairing operational leverage and constraining enterprise reinvestment.
Warning level: Filed regulatory rejection, trial termination, or clinical suspension of a lead Phase 3 candidate within 12 months. Clinical setbacks eliminate anticipated successor revenue streams required to replace maturing legacy blockbusters, exposing the business to patent cliffs and severe volume losses.
Warning level: Exceeds 100.0% over any trailing twelve-month period. Distributing more cash than generated forces management to divert liquidity from capital expenditures or take on debt to sustain shareholder distributions, creating imminent risk of distribution reductions.
Warning level: Drops below 1.0x over any four-quarter measurement period. Cash generation lagging reported earnings highlights working capital absorption or aggressive revenue accruals, undermining earnings quality and reducing discretionary cash available for balance sheet flexibility.
| الهامش |
|---|
| SNY | Sanofi | $104.3B | 8.4x | 2.2x | 5.2x | — | — |
| LLY | Eli Lilly and Company | 23.0x | 12.6x | 26.2x | 107.5% | 49.4% | |
| JNJ | Johnson & Johnson | 18.1x | 5.7x | 17.1x | 26.4% | 27.4% | |
| ABBV | AbbVie Inc. | 13.2x | 6.0x | 14.5x | 62.2% | 32.2% | |
| MRK | Merck & Co. Inc. | 12.0x | 4.3x | 11.0x | 18.9% | 38.6% | |
| AMGN | Amgen Inc. | 14.1x | 4.8x | 13.2x | 101.3% | 33.8% |
